Novo's diabetes drug shown to decrease heart risks, boosting competitive edge

Victoza is only the second drug for the metabolic condition to demonstrate a cardiovascular benefit. 

By Nicole Gray • June 14, 2016

Merck, Pfizer expand trial studying CV benefit of experimental diabetes drug

The companies recently announced the drug, ertugliflozin, had met its primary endpoints in two phase 3 trials. 

By Nicole Gray • June 13, 2016

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

Sanofi's diabetes drug hits trial targets, heads for final approval

A FDA vote on LixiLan is expected in August.

By Randy Lilleston • June 13, 2016

Lilly presents solid long-term data for baricitinib in RA patients

The patients experienced significantly significant improvements in pain, fatigue, physical function and physical health-related quality of life.

By Nicole Gray • June 12, 2016

Amgen's chronic migraine-prevention drug shows promise in midstage trials

Alder Biopharmaceuticals, Lilly and Teva are also at work on chronic-migraine drugs that target the CGRP receptor. 

By Nicole Gray • June 10, 2016

Study: Blood-based 'liquid biopsy' cancer testing works

A study that included genetic information from 15,000 patients across 50 tumor types confirmed the accuracy of the tests for diagnostic and tumor-tracking purposes. 

By Nicole Gray • June 8, 2016

Kite, Juno anticipating 2017 approvals for T-cell therapy

The two companies, both recognized CAR-T front-runners, are aiming for FDA approvals for treatment of blood cancers by next year.  

By Nicole Gray • June 8, 2016

Biogen's MS drug fails phase 2 trial

Biogen says that it has seen evidence of the drug's clinical effect and will further analyze data for a path forward. 

By Shalina Chatlani • June 8, 2016

Small biotech Accera reinvents itself, takes aim at Alzheimer's treatment

BioPharma Dive spoke to Charles Stacey, CEO of Accera, about its ongoing Phase 3 study for a new kind of Alzheimer's drug. 

By Ned Pagliarulo • June 8, 2016

Alexion's Soliris fails in late-stage myasthenia gravis trial

The treatment generated $2.59 billion in sales last year. 

By Nicole Gray • June 7, 2016

FDA asks Sarepta for more data on muscular dystrophy drug

Shares of Sarepta jumped 25% higher in late trading Monday, as investors continue to hope for a path to approval for eteplirsen. 

By Ned Pagliarulo • June 7, 2016

Regeneron/Sanofi's dupilumab shines in phase 3 eczema trial

Analysts are looking for up to $2.5 billion in peak sales for dupilumab. 

By Nicole Gray • June 6, 2016

Study: Bristol-Myers' immunotherapy combo boosts response in lung cancer

Previous studies of Opdivo and Yervoy administered together had shown benefit in treating melanoma. 

By Nicole Gray • June 6, 2016

Roche positioning Tecentriq as first-line therapy in bladder cancer

It is the first new therapy approved for bladder cancer in 30 years. 

By Nicole Gray • June 6, 2016

Mylan's Herceptin biosim shows comparable efficacy/safety

There has not been one biosimilar approved in the EU or the U.S. to treat cancer. 

By Nicole Gray • June 6, 2016

AbbVie lung cancer drug shows promise, but has high expectations to meet

The drug, called Rova-T, was acquired by AbbVie earlier this year after its acquisition of Stemcentrx. 

By Ned Pagliarulo • June 5, 2016

Global cancer drug spending rises, set to surpass $150 billion by 2020

A wave of new drugs entering the market over the past five years has helped drive spending higher, according to a new report from IMS Health.

By Ned Pagliarulo • June 2, 2016

Kite Pharma rides CAR-T momentum into ASCO

BioPharma Dive spoke to the immuno-oncology biotech to find out how its lead cell therapy is progressing as it aims for a 2017 launch.

By Nicole Gray • June 2, 2016

Daiichi Sankyo halts late-stage study of lung cancer drug

But the company stood by the underlying science of patritumab and said it would press forward with development in head and neck cancers. 

By Nicole Gray • June 1, 2016

BioMarin ends Duchenne program, withdraws EU application for drisapersen

The decision brings BioMarin's current Duchenne program to a close, two years after the company paid $680 million to acquire Prosensa for rights to drisapersen.

By Ned Pagliarulo • May 31, 2016

Contract researcher BioClinica reportedly weighing sale

The CRO market has been consolidating with major mergers announced or rumored over the past year. 

By Nicole Gray • May 27, 2016

Roche's Gazyva notches early trial success

The Swiss company hopes the blood cancer drug can be a new source of growth as several older drugs face biosimilar competition. 

By Ned Pagliarulo • May 27, 2016

FDA rejects AstraZeneca hyperkalemia drug, boosting competitor Relypsa

AstraZeneca had acquired the drug last fall in a $2.7 billion deal for ZS Pharma. 

By Ned Pagliarulo • May 27, 2016

EMA reportedly reviewing clinical guidelines in wake of fatal drug trial

A report from French regulators concluded Portuguese drugmaker Bial and CRO Biotrial made several key mistakes in a January trial which left one man dead and hospitalized five others. 

By Nicole Gray • May 25, 2016

Despite recent R&D setbacks, Lilly aims to launch 20 new drugs by 2023

Although Lilly has struggled to replace aging drugs, CEO John Lechleiter sees the decade from 2014 to 2023 as "the most prolific period of new launches" in the company's history. 

By Ned Pagliarulo • May 24, 2016